HCW Biologics raises $1.5 million in private offering, Form D shows

HCW Biologics Inc., based in Miramar, Florida, filed a Form D with the Securities and Exchange Commission disclosing a private securities offering. The filing is listed as a new notice with a date of first sale of September 24, 2026.¹

The total offering amount was $1,500,000, and the company reported the full $1,500,000 had already been sold, leaving nothing remaining to be sold.¹ The company listed one investor who had already put money into the offering.¹

The offering relied on an exemption under Rule 506(b)¹ of Regulation D. The securities offered included equity, an option, warrant or other right to acquire another security, and a security to be acquired upon exercise of such an option, warrant or right.¹ The company stated the offering was not being made in connection with a business combination transaction such as a merger, acquisition or exchange offer.¹

On compensation and proceeds, the filing reported no sales commissions or finders' fees tied to the deal. Both sales commissions and finders' fees were listed as $0.¹ For the amount of gross proceeds used to pay any executive officers, directors or promoters named in the filing, the company also reported $0.¹

The company indicated it does not intend the offering to last more than one year.¹ The minimum investment accepted from any outside investor was listed as $0.¹

The notice was signed by Rebecca Byam, identified as Chief Financial Officer, on October 8, 2026, per the filing's signature block.